Cytokinetics (NASDAQ:CYTK) will be releasing its earnings data after the market closes on Thursday, February 21st. Analysts expect Cytokinetics to post earnings of ($0.55) per share for the quarter.
NASDAQ:CYTK opened at $7.60 on Thursday. Cytokinetics has a 52-week low of $5.90 and a 52-week high of $10.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 10.58 and a current ratio of 10.57. The firm has a market cap of $409.79 million, a price-to-earnings ratio of -2.93 and a beta of 2.17.
Several research firms have issued reports on CYTK. BidaskClub downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Thursday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Cytokinetics in a report on Tuesday, January 22nd. ValuEngine raised Cytokinetics from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. Finally, Zacks Investment Research raised Cytokinetics from a “sell” rating to a “hold” rating and set a $8.00 price objective on the stock in a report on Friday, November 2nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Cytokinetics currently has an average rating of “Buy” and an average target price of $12.79.
In other Cytokinetics news, CEO Robert I. Blum sold 4,000 shares of the company’s stock in a transaction on Friday, January 4th. The stock was sold at an average price of $7.11, for a total transaction of $28,440.00. Following the transaction, the chief executive officer now owns 148,022 shares of the company’s stock, valued at approximately $1,052,436.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 12,500 shares of company stock worth $91,395. Company insiders own 5.10% of the company’s stock.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Featured Article: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.